Acupuncture and Escitalopram for Treating Major Depression Clinical Study

NANot yet recruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

February 28, 2027

Conditions
Depressive Disorder, Major
Interventions
OTHER

acupuncture

"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."

OTHER

escitalopram

Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.

OTHER

sham-acupuncure

In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.

OTHER

escitalopram placebo

Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.

Trial Locations (3)

200030

Jianhua Chen, Shanghai

200137

Zhenxiang Han, Shanghai

Unknown

Zouqing Huang, Shanghai

All Listed Sponsors
lead

Shanghai 7th People's Hospital

OTHER

NCT05901571 - Acupuncture and Escitalopram for Treating Major Depression Clinical Study | Biotech Hunter | Biotech Hunter